Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
Showing 1199 results
April 2015
-
Media ReleaseData at AAN showed Gilenya® high efficacy in achieving 'no evidence of disease activity' in previously-treated highly-active MS patientsNew FREEDOMS/FREEDOMS II sub-group analysis showed Gilenya-treated patients were six-times more likely to achieve 'no evidence of disease activity (NEDA4)' vs placebo NEDA4 is based on four…
-
Media ReleaseSandoz receives FDA approval for GlatopaTM as the first generic competitor to MS therapy Copaxone® 20mgGlatopa is the first FDA-approved, substitutable generic version of Copaxone® 20mg, a treatment for relapsing forms of multiple sclerosis Novartis and Sandoz are driving access to a full…
-
Media ReleaseAlcon receives FDA approval of new multifocal intraocular lens to treat cataract patients in the United StatesUS Food and Drug Administration (FDA) grants approval of the AcrySof® IQ ReSTOR® +2.5 Diopter (D) Intraocular Lens (IOL) for sale in the US Expands Alcon's IOL portfolio for the …
-
Media ReleaseData in The Lancet show Novartis drug Arzerra® plus chlorambucil improved median progression-free survival by 71% in CLL patientsSignificant improvement in PFS seen with Arzerra plus chlorambucil in previously untreated patients with CLL for whom fludarabine-based therapy was inappropriate Chronic lymphocytic…
-
Media ReleaseGilenya® data at AAN to highlight Novartis leadership in innovation with new MS assessment methods to benefit patients and physiciansNew analysis will confirm high efficacy of Gilenya® in achieving 'no evidence of disease activity' (NEDA4) in previously-treated highly-active RMS patients Separate analyses will show adding…
March 2015
-
Media ReleaseNovartis announces FDA approval for JadenuTM to simplify treatment administration for patients with chronic iron overloadJadenu (deferasirox), a new formulation of Exjade (deferasirox), is the only once-daily oral tablet for iron chelation Jadenu, taken with or without food, simplifies daily treatment…
-
Media ReleaseNovartis accelerates cancer immunotherapy efforts with Aduro Biotech alliance and launch of new immuno-oncology research groupCollaboration with Aduro is focused on discovery and development of next generation cancer immunotherapies targeting the STING signaling pathway Addition of STING agonists further enhances…
-
Media ReleaseNovartis' Cosentyx(TM) two-year data shows sustained effect and favorable safety profile in psoriasis patientsAfter two full years of therapy with Cosentyx 300 mg, almost 9 out of 10 psoriasis patients sustained their PASI 75 response[1] New data at AAD shows 7 out of 10 psoriasis patients, who…
-
Media ReleaseNew Novartis data shows Cosentyx(TM) is significantly superior to Stelara® and clears skin (PASI 90) in nearly 80% of psoriasis patientsCLEAR study at AAD showed over 21% more psoriasis patients achieved clear to almost clear skin (PASI 90) with Cosentyx(TM) compared to Stelara® at Week 16[1] Cosentyx showed greater improvements…
-
Media ReleaseNovartis receives EU approval for Jakavi® in polycythemia vera, first targeted therapy approved for patients with this rare blood cancerJakavi® (ruxolitinib) approved by the European Commission for adult patients with polycythemia vera (PV) resistant to or intolerant of hydroxyurea PV is a rare blood cancer associated with…
-
Media ReleaseNovartis to present new late-breaking CosentyxTM data at AAD 2015 showing significant patient benefit in achieving clear skinDetailed results from the CLEAR study will be revealed showing Cosentyx superiority to Stelara® in clearing skin (PASI 90 and PASI 100)[1] New data from the long-term Phase III program to…
-
Media ReleaseFDA approves first biosimilar ZarxioTM (filgrastim-sndz) from SandozSandoz is the first company to receive approval of a biosimilar in the US through the new FDA biosimilars pathway established under BPCIA Zarxio is approved for all indications included in the…